Profitable MorphoSys Proves Value of Technology Partnership Model
This article was originally published in The Pink Sheet Daily
Executive Summary
A milestone payment from long-time partner Novartis helped German antibody company MorphoSys report record revenues, supporting a 23% increase in R&D spend without the need to tap investors.